Truist Financial’s LB Pharmaceuticals LBRX Stock Holding History

Truist Financial’s Portfolio LBRX Stock Details LBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$326K	Buy	+8,800	New	+$364K	﹤0.01%	2471

Other funds holding LBRX

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Sigma Planning Corp Ann Arbor, Michigan $3.88B AUM 23.38% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Meyer Handelman Company Rye Brook, New York $3.49B AUM 26.82% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

State of Wyoming Cheyenne, Wyoming $1.29B AUM 32.25% 1-Year Est. Return

Truist Financial's LBRX Position: Q3 2026 in Review

Truist Financial opened a new position in LB Pharmaceuticals (LBRX) in Q3 2026: 8,800 shares worth $326K. The stake represents ﹤0.01% of the portfolio and ranks #2471 among its holdings.

19 funds tracked by Wall St. Rank hold LBRX as of Q3 2026.

Truist Financial held 8,800 shares of LB Pharmaceuticals worth $326K as of Q3 2026.
LB Pharmaceuticals was a new Truist Financial position in Q3 2026.
LB Pharmaceuticals made up ﹤0.01% of Truist Financial's portfolio in Q3 2026, its #2471 holding.
19 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q3 2026.

Based on Truist Financial's 13F filing for Q3 2026, filed 30 Oct 2026.